GLUCAGON-LIKE peptide-1 receptor agonists (GLP-1 RAs) are more effective for women than men when it comes to weight loss, according to a large review published in JAMA Internal Medicine today.
Researchers looking at findings from 64 trials found that apart from sex differences, the efficacy of GLP-1 RAs appeared to be consistent across age, race and ethnicity, baseline body mass index, and baseline haemoglobin A1c.
The researchers suggested this could be due to "the ability of GLP-1 RAs to synergistically interact with oestrogens as well as the potential for altered pharmacokinetics and greater response among women because of their lower median body weight".
"These study findings may be useful to stakeholders vested in improving the care of individuals with obesity, diabetes, and other conditions for which GLP-1 RAs may be indicated," they concluded.
Read the study HERE.
Meanwhile, results from a phase 3 trial of GLP-1 RA pill orforglipron have reported a larger reduction in blood sugar levels after one year than the currently available oral GLP-1 RA, semaglutide.
Patients taking orforglipron also had significantly greater reductions in body weight than those taking oral semaglutide.
The trial involved over 1,500 people with type 2 diabetes from 131 medical research centres and hospitals in various countries.
With an average starting weight of 97kg, those taking orforglipron lost on average 6-8% of their weight, depending on the dose, compared with 4-5% with semaglutide.
However, more people dropped out of the trial due to gastrointestinal side effects when taking orforglipron (9-10%) than when using semaglutide (4-5%).
Read the study HERE. KB
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Mar 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Mar 26
